RecruitingNCT05700773

The Relationship Between Myonectin Concentration and the Course of ST-segment Elevation Myocardial Infarction

Assessing the Relationship Between Myonectin Concentration and the Course of Hospitalization and the 30-day Risk of Cardiac Endpoints in Patients With the First Incident of ST-segment Elevation Mycardial Infarction Treated With Primary PCI


Sponsor

Michał Jaśkiewicz

Enrollment

100 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study is to test the potentially protective role of myonectin in patients with a first episode of ST elevation myocardial infarction (MI) treated with primary percutaneous coronary intervention (PCI). The main questions which are assumed to be answered after study completion: 1. Does higher myonectin concentration influence the in-hospital and 30-day course of the first ST-elevation MI in patients treated with primary coronary angioplasty 2. Is there a relationship between the serum myonectin concentration, related to patient's nutritional status and physical activity with the patient's physical activity declared as usually before the coronary event occurrence, the cardiac biomarkers level, and myocardial and skeletal muscle mass determined in order to objectify the relationship of physical activity before the infarction with 30-day and one-year mortality, and the other primary and secondary outcomes measured at 12-month visit, e.g. the extent of myocardial infarction, 3. Is there a relationship between the baseline concentration of myonectin and troponin with the control of atherosclerosis risk factors, declared physical activity and parameters of body composition, outcome of treadmill exercise test, values of echocardiographic parameters and myonectin concentration 12 months after a cardiovascular incident


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

  • symptoms of acute coronary syndrome
  • acute ST segment elevation in two or more leads in ECG
  • primary PCI

Exclusion Criteria10

  • pregnancy
  • patients unconscious, with altered consciousness or not able to cooperate
  • cardiogenic shock
  • significant physical effort within 24 hours before onset of MI
  • active infection at admission, intramuscular injection
  • myocardial infarction in patient's medical history
  • heart failure New York Heart Association (NYHA) class III - IV in patient's medical history
  • renal failure (chronic kidney disease, CKD) with glomerular filtration rate (GFR) < 30ml/min
  • history of malignant neoplasms in the last 5 years
  • patients incapacitated, active soldiers, imprisoned or related with investigators

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Voivodeship Hospital in Elblag

Elblag, Warmian-Masurian Voivodeship, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05700773


Related Trials